Trends in Dispensing of Zolpidem and Low-Dose Trazodone Among Commercially Insured Adults in the United States, 2011-2018

Jenna Wong; Mara Murray Horwitz; Suzanne M Bertisch; Shoshana J Herzig; Daniel J Buysse; Sengwee Toh

doi:10.1001/jama.2020.19224

Trends in Dispensing of Zolpidem and Low-Dose Trazodone Among Commercially Insured Adults in the United States, 2011-2018

JAMA. 2020 Dec 1;324(21):2211-2213. doi: 10.1001/jama.2020.19224.

Authors

Jenna Wong¹, Mara Murray Horwitz², Suzanne M Bertisch³, Shoshana J Herzig⁴, Daniel J Buysse⁵, Sengwee Toh¹

Affiliations

¹ Department of Population Medicine, Harvard Medical School, Boston, Massachusetts.
² Department of Medicine, Boston Medical Center, Boston, Massachusetts.
³ Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, Massachusetts.
⁴ Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
⁵ Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Abstract

This study uses IBM MarketScan database data to describe trends in zolpidem and low-dose trazodone dispensing among adults with employer-sponsored insurance or Medicare supplemental plans between 2011 and 2018, before and after a 2017 clinical practice guideline discouraged trazodone use for insomnia.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Drug Prescriptions / statistics & numerical data*
Female
Health Benefit Plans, Employee
Humans
Insurance, Medigap
Male
Practice Patterns, Physicians' / trends*
Sleep Aids, Pharmaceutical / therapeutic use*
Trazodone / administration & dosage
Trazodone / therapeutic use*
United States
Zolpidem / therapeutic use*

Substances

Sleep Aids, Pharmaceutical
Zolpidem
Trazodone